Literature DB >> 15130273

The role of radiotherapy in the treatment of liver metastases.

Laura A Dawson1, Theodore S Lawrence.   

Abstract

Radiotherapy has historically played a minor role in the treatment of patients with unresectable liver metastases from colorectal cancer and other malignancies. This can be attributed chiefly to the low tolerance of the whole liver to radiation. High-precision radiotherapy planning techniques have allowed much higher doses of radiation to be delivered safely to focal liver metastases, while sparing most of the normal liver. When combined with hepatic arterial fluorodeoxyuridine, high-dose focal liver radiotherapy is associated with excellent response rates, local control, and survival in patients with unresectable liver metastases from colorectal cancer. Radiotherapy, with and without concurrent systemic chemotherapy, has also been used with encouraging outcomes for patients with liver metastases from colorectal cancer and other cancers. There appears to be a radiation dose response for liver metastases; tumors treated with doses of 70 Gy or greater are likelier to have durable local control. Advancements in tumor imaging, in radiotherapy techniques that will allow the safe delivery of higher doses of radiation, and in novel tumor radiation sensitizers and normal tissue radioprotectors should substantially improve the outcome of patients with unresectable liver metastases treated with radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15130273     DOI: 10.1097/00130404-200403000-00009

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  5 in total

Review 1.  Radioimmunotherapy of solid tumors: searching for the right target.

Authors:  Hong Song; George Sgouros
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

2.  Mechanisms of substrate selectivity for Bacillus anthracis thymidylate kinase.

Authors:  Cecilia Carnrot; Liya Wang; Dimitri Topalis; Staffan Eriksson
Journal:  Protein Sci       Date:  2008-06-03       Impact factor: 6.725

3.  Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer.

Authors:  Marta Scorsetti; Tiziana Comito; Angelo Tozzi; Pierina Navarria; Antonella Fogliata; Elena Clerici; Pietro Mancosu; Giacomo Reggiori; Lorenza Rimassa; Guido Torzilli; Stefano Tomatis; Armando Santoro; Luca Cozzi
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-23       Impact factor: 4.553

4.  Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology.

Authors:  R Biffi; F Orsi; M G Zampino; A Chiappa; N Fazio; F De Braud; G Bonomo; L Monfardini; P D Vigna; F Luca; L Bodei; M Bartolomei; G Catalano; M C Leonardi; M Ferrari; B Andreoni; A Goldhirsch; G Paganelli; R Orecchia
Journal:  Ecancermedicalscience       Date:  2008-05-02

5.  What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy.

Authors:  Chie Toramatsu; Norio Katoh; Shinichi Shimizu; Hideaki Nihongi; Taeko Matsuura; Seishin Takao; Naoki Miyamoto; Ryusuke Suzuki; Kenneth Sutherland; Rumiko Kinoshita; Rikiya Onimaru; Masayori Ishikawa; Kikuo Umegaki; Hiroki Shirato
Journal:  Radiat Oncol       Date:  2013-03-05       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.